CBG, CBN and CBC are cannabinoids found in cannabis. They are often called “minor cannabinoids” because they are commonly present in lower amounts than THC or CBD. “Minor” describes relative presence, not importance, quality or a predicted effect.
A report that names one of these compounds identifies a measured constituent. The useful next question is how that measurement relates to the formulation, the evidence cited and the prescribed-care record.
CBG research in people and laboratory models
CBG means cannabigerol. Laboratory studies have measured activity at receptors, and a rat feeding experiment reported changes in food intake under its study conditions. Neither design tests a patient outcome.
A small double-blind crossover study in healthy adults examined acute CBG effects on anxiety, stress, mood and performance measures. A later randomised placebo-controlled trial in veterans with sleep problems found no statistically significant difference on its main sleep-quality measure and had substantial attrition. These are useful, limited studies in defined populations and formulations; they do not show that a CBG percentage predicts anxiety, appetite, mood or sleep in a prescribed product. See the CBG evidence page.
CBN and sleep studies
CBN means cannabinol. It is frequently marketed with sleep language. A 2023 double-blind, randomised placebo-controlled trial tested defined oral CBN preparations, with and without CBD, in adults who reported poor sleep. Some sleep-disturbance measures changed, while other outcomes did not. Another randomised trial of branded CBN formulations did not establish that CBN was superior to melatonin on the reported sleep measure.
Those findings do not turn CBN into a general sleep treatment or make a CBN-containing flower, oil or mixed-cannabinoid product equivalent to the study preparations. The CBN page sets out that boundary in more detail.
CBC pharmacokinetics and receptor research
CBC means cannabichromene. A human pharmacokinetic study measured CBC after people received a product that also contained CBD and THC. It described what was measurable in blood from that multi-cannabinoid formulation; it did not isolate CBC or test a patient benefit. Other cited CBC work is receptor pharmacology in engineered cells or metabolism research in laboratory-animal tissue.
That makes CBC an example of why a constituent name must not be turned into a clinical label. Read the CBC evidence page for the study types and limits.
Minor cannabinoids on a laboratory report
A laboratory report can show that CBG, CBN or CBC was detected or measured in that sample. It does not show that the product is medically authorised, that the study formulation was matched, or that a person will have the response reported in a different population. It cannot decide product choice, dose, route, suitability, impairment or driving status.
Do not collapse all cannabinoid evidence together. The evidence base for CBD and THC has different study histories and UK regulatory questions. The MCPH cannabinoid reference keeps those distinctions visible.
Minor cannabinoids in a prescription record
Minor cannabinoids are real constituents, and research is developing. A percentage or marketing description does not settle a question about a prescribed product. The exact dispensing information, discussed with the prescriber or pharmacist, is the relevant starting point. The glossary explains the terms that appear in those records.
Sources
- Acute effects of cannabigerol on anxiety, stress, and mood (PMID 39003387); double-blind placebo-controlled crossover study in healthy adults; not a patient-treatment trial.
- Effect of Cannabigerol on Sleep and Quality of Life in Veterans (PMID 41574318); triple-blind randomised placebo-controlled trial; its main sleep-quality measure was not statistically different from placebo and attrition was substantial.
- Safety and effects of CBN with and without CBD on sleep quality (PMID 37796540); double-blind randomised placebo-controlled trial using defined oral preparations and short follow-up; it does not establish a general sleep treatment.
- Pharmacokinetics of cannabichromene in a medical cannabis product containing CBD and THC (PMID 34664109); human multi-cannabinoid pharmacokinetic analysis; it does not isolate CBC effects.
- Cannabichromene is a cannabinoid CB2 receptor agonist (PMID 31368508); engineered-cell receptor study, not a patient-outcome study.
